CMB.TECH 12.680 € (+0,32 %) RECTICEL 10.460 € (+0,77 %) AGEAS 67.800 € (+0,74 %) ARGENX SE 687.600 € (-0,12 %) AB INBEV 67.970 € (-3,40 %) UCB 235.600 € (-0,17 %) TUBIZE-FIN 201.000 € (-0,69 %) WDP 22.500 € (-0,53 %) MELEXIS 76.800 € (+0,13 %) ELIA GROUP 137.600 € (-1,22 %) SOLVAY 26.140 € (-9,42 %) BEKAERT 44.200 € (+0,45 %) AZELIS GROUP 10.450 € (-3,24 %) DEME GROUP 204.500 € (+0,49 %) SYENSQO 57.850 € (-1,62 %) BPOST 1.640 € (-3,53 %) XIOR 27.900 € (+0,72 %) RETAIL ESTATES 67.600 € (-0,73 %) BARCO 9.075 € (-1,25 %) KBC ANCORA 80.400 € (+0,50 %) KBC 116.750 € (+0,60 %) PROXIMUS 6.605 € (0,00 %) TITAN S.A. 51.650 € (+4,55 %) NYXOAH 2.750 € (+1,29 %) ACKERMANS V.HAAREN 296.000 € (-0,13 %) UMICORE 21.420 € (+3,08 %) GIMV 48.900 € (+0,62 %) ONTEX GROUP 2.890 € (-0,17 %) EKOPAK 4.500 € (+1,01 %) COLRUYT 32.400 € (-2,00 %) TESSENDERLO 21.700 € (0,00 %) ORANGE BELGIUM 21.200 € (0,00 %) VIOHALCO 17.600 € (+1,38 %) CIE BOIS SAUVAGE 329.000 € (+0,92 %) OXURION 0.004 € (0,00 %) SHURGARD 26.250 € (+0,57 %) EVS BROADC.EQUIPM. 37.550 € (+0,40 %) LOTUS BAKERIES 10 860.000 € (+1,12 %) FLUXYS BELGIUM D 22.200 € (-1,77 %) MONTEA 69.500 € (-1,84 %) VASTNED 28.900 € (+1,05 %) D'IETEREN GROUP 182.300 € (-0,92 %) AEDIFICA 72.450 € (-0,41 %) COFINIMMO 84.900 € (-0,59 %) BIOTALYS 2.915 € (-2,18 %) TINC 12.100 € (-0,66 %) SOFINA 221.000 € (-1,52 %) FAGRON 24.700 € (-0,60 %) DECEUNINCK 2.070 € (+0,49 %) IBA 14.820 € (+0,27 %) KINEPOLIS GROUP 30.400 € (+0,16 %) CFE 11.700 € (+0,43 %) ONWARD MEDICAL 2.720 € (+0,74 %) CELYAD ONCOLOGY 0.310 € (-2,52 %) GBL 81.950 € (-0,30 %) ECONOCOM GROUP 1.400 € (0,00 %) BREDERODE 102.800 € (-0,19 %) INCLUSIO SA/NV 17.650 € (-0,84 %) SIPEF 100.000 € (-1,38 %) HOME INVEST BE. 19.200 € (-0,93 %)
TITAN 2.700 € (-14,01 %)
EMEIS 15.400 € (+0,72 %)
AYVENS 11.300 € (-0,88 %)
OPMOBILITY 15.700 € (+1,36 %)
FERROVIAL 60.600 € (-0,46 %)
PLANISWARE 17.950 € (+0,50 %)
FDJ UNITED 22.880 € (-0,44 %)
CARREFOUR 17.145 € (+0,03 %)
THALES 237.000 € (-1,66 %)
LVMH 484.050 € (+2,12 %)
EUROFINS SCIENT. 60.260 € (+0,43 %)
VEOLIA ENVIRON. 36.460 € (+0,72 %)
GTT 209.600 € (-0,47 %)
DASSAULT AVIATION 305.000 € (-0,91 %)
GALP ENERGIA-NOM 19.010 € (-1,48 %)
AIR LIQUIDE 177.460 € (-1,56 %)
STMICROELECTRONICS 48.715 € (+0,44 %)
ELIS 28.060 € (+1,67 %)
AIRBUS 185.960 € (-1,35 %)
ENGIE 27.280 € (-1,05 %)
SCHNEIDER ELECTRIC 283.850 € (+0,41 %)
EXAIL TECHNOLOGIES 115.000 € (-5,27 %)
ALTEN 62.400 € (+0,89 %)
SAFRAN 299.400 € (+0,91 %)
BONDUELLE 8.160 € (-4,23 %)
PUBLICIS GROUPE SA 81.800 € (+0,15 %)
BOUYGUES 51.320 € (-3,17 %)
74SOFTWARE 37.200 € (+0,54 %)
SOCIETE GENERALE 70.830 € (+1,19 %)
L'OREAL 370.950 € (-0,66 %)
UBISOFT ENTERTAIN 4.855 € (-1,40 %)
TOTALENERGIES 75.260 € (-1,94 %)
ABIVAX 106.800 € (-3,09 %)
PROSUS 42.385 € (+1,21 %)
AXA 41.620 € (-0,43 %)
ASML HOLDING 1 306.000 € (+0,08 %)
SANOFI 73.930 € (-0,95 %)
SOITEC 150.450 € (+2,45 %)
WOLTERS KLUWER 61.540 € (-2,96 %)
COFACE 16.260 € (+0,56 %)
ADOCIA 5.075 € (+5,64 %)
ADYEN 964.300 € (+0,70 %)
RELX 28.760 € (-5,27 %)
UNILEVER 50.510 € (-0,30 %)
AEGON 7.168 € (+0,06 %)
PHARMING GROUP 1.099 € (-21,22 %)
SHELL PLC 36.385 € (-2,06 %)
ABN AMRO BANK N.V. 30.560 € (+1,13 %)
BUREAU VERITAS 26.860 € (+0,22 %)
SMCP 5.255 € (+0,77 %)
BNP PARIBAS ACT.A 93.720 € (+0,33 %)
CSG 16.368 € (-4,03 %)
ESSILORLUXOTTICA 177.600 € (+0,51 %)
GALAPAGOS 24.160 € (-1,87 %)
IMCD 95.960 € (-1,92 %)
DASSAULT SYSTEMES 19.715 € (-0,28 %)
VIRBAC 372.500 € (+0,27 %)
NN GROUP 75.760 € (+0,08 %)
EXOR NV 68.550 € (+1,11 %)
RUBIS 35.500 € (-1,93 %) News Réglementées
|
17/04/2026 09:00
Original-Research: NFON AG (von NuWays AG): BUYOriginal-Research: NFON AG - from NuWays AG Classification of NuWays AG to NFON AG
Trading still soft but AI acceleration set to kick in Yesterday, NFON published its FY25 annual report, confirming the preliminary figures released in February and providing additional colour on the AI transformation and FY26 outlook. In detail: FY25 recap. Sales grew 2.0% to € 89.1m (thereof 92.1% recurring) while adj. EBITDA came in at € 12.6m (+2.4%, 14.2% margin). The only notable delta vs. the prelims was the ARPU, which reached € 10.01 (FY25p: € 9.91; FY24: € 9.89), crossing the important threshold of € 10. The ARPU uptick thus offset the 2.7% decline of the seat base to 647k, which was driven by lower order intake and prolonged sales cycles rather than inflated churn (stable at 0.5% p.m.). Strong AI momentum. Since the launch of new AI features like NIA, NFON is making tangible progress in embedding AI across its platform, with triple-digit growth in intelligent assistant solutions and increasing ARPU driven by AI upsell. Early partner feedback and use case deployment suggest strong product-market fit, particularly in automation and customer engagement. However, monetization remains at an early stage and is not yet offsetting weakness in the core PBX business. Near-term visibility is therefore limited, with execution risk around scaling adoption and converting growing AI usage into sustained revenue contribution. Macro continues to weigh operations. During the CC, management hinted that trading into 2026 remains subdued, with continued muted demand, elongated sales cycles and a cautious SME customer base delaying investment decisions. While Q4 showed some stabilisation in seat trends, this has not yet translated into a broader recovery, and visibility on new business remains limited. Hence, we expect underlying volumes to remain under pressure at least throughout H1 (eNuW: +0.9% sales), with growth primarily driven by pricing, mix and early AI related upsell, rather than a genuine demand recovery. Yet, despite current, mostly macro related, headwinds we continue to see the underlying case as intact. NFON is transitioning from a volume-driven PBX provider to a value-driven AI communications platform, with early signs of success reflected in rising ARPU and strong growth in new solution areas. While execution risks around scaling AI monetisation remain, the combination of a highly recurring revenue base, disciplined cost control and increasing partner leverage provides a solid foundation for dynamic top-line development and further margin expansion in the mid-term. Against this backdrop, current valuation levels appear undemanding as shares are trading at a mere 5.3x FY26e EV/adj. EBITDA. Reiterate BUY with a new PT of € 8.30 (old: € 8.70) based on DCF. You can download the research here: nfon-ag-2026-04-17-previewreview-en-8720c For additional information visit our website: https://www.nuways-ag.com/research-feed Contact for questions: NuWays AG - Equity Research Web: www.nuways-ag.com Email: research@nuways-ag.com LinkedIn: https://www.linkedin.com/company/nuwaysag Adresse: Mittelweg 16-17, 20148 Hamburg, Germany ++++++++++ Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte. Offenlegung möglicher Interessenkonflikte nach § 85 WpHG beim oben analysierten Unternehmen befindet sich in der vollständigen Analyse. ++++++++++ The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 2310200 17.04.2026 CET/CEST Source : Webdisclosure.com |
||||||||||||||||||
© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière